Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Johnson Bottini Files Class Action Lawsuit Against Sequenom
The complaint alleges that on April 29, 2009, after the market closed, Sequenom announced that the expected launch of its SEQureDxTM Down syndrome test will be delayed because
The complaint alleges that on April 29, 2009, after the market closed, Sequenom announced that the expected launch of its SEQureDxTM Down syndrome test will be delayed because
Outlook 2009 Novo Nordisk still expects sales growth in 2009 at the level of 10% measured in local currencies. This is based on expectations of continued market penetration
Updated 2009 Financial Guidance We are updating our guidance based on our solid first-quarter performance and our Tepnel acquisition, said Herm Rosenman, the Company’s senior vice president of
As of March 31, 2009, the company’s cash, cash equivalents, investments and settlement rights associated with certain auction rate securities totaled $194.6 million. Total operating costs and expenses
NanoViricides, a nano-biopharmaceutical company, has reported that it is developing FluCide, its flagship anti-influenza drug candidate, to work against all influenza types and subtypes. FluCide has been shown
Ocera Therapeutics, a biopharmaceutical company, has reported positive data from its Phase II study of AST-120 for the treatment of patients with low-grade hepatic encephalopathy. The study showed
Isotechnika, a biopharmaceutical company, has reported that its Essence Phase III trial of voclosporin in moderate to severe psoriasis patients successfully met the primary endpoint of superiority to
The company reported net revenues of $5.38 billion for the first quarter of 2008, a decrease of 6%, compared to $5.71 billion for the first quarter of 2008.
According to Novartis, these data reinforce previous results from the Transforms study announced in December 2008 showing that the relapse rate at one year was 52% lower in
In the Phase IIa trial of 129 migraine patients, significantly more patients taking ADX10059 than those taking placebo (16.7% versus 4.7%, respectively p = 0.039) were pain-free two